Nuvation Bio logo

Nuvation Bio

NUVB | NYSE
Chart Builder DCF Calculator
$3.84
-$0.15 (-3.76%)
At close: Nov 16, 2026, 4:00 PM ET
$3.84
$0.00 (0.00%)
After-hours: Nov 16, 2026, 6:41 PM ET
-3.76%

Rating

Updated: Nov 16, 2026
55.8
Fundamentals Strong
Market Sentiment Neutral
Moat Narrow
Sector Rank #173/1021 (Top 17%)

Key Statistics

Market Data

Market Cap $1.35B
1D Range
3.82 4.00
52W Range
3.82 9.54

Valuation (TTM)

PE -9.60
PB 5.93
EV/EBITDA -10.76

Valuation (NTM)

Forward PE N/A
Forward PEG 0.32
Price Target $20.00
Loading financial charts...

Profile

Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound...

Sector Healthcare
Industry Biotechnology
Employees 305
IPO Date Aug 26, 2020
Fiscal Year January - December

Latest News

Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting

17 hours ago · gurufocus.com

Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting
Nuvation Bio: The Market Is Counting New Starts While IBTROZI Stacks Patients

8 days ago · seekingalpha.com

Nuvation Bio: The Market Is Counting New Starts While IBTROZI Stacks Patients
What Nuvation Bio (NUVB) Said on Its Q3 Earnings Call

9 days ago · marketbeat.com

What Nuvation Bio (NUVB) Said on Its Q3 Earnings Call
Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript

12 days ago · seekingalpha.com

Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript
Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Beats Revenue Estimates

12 days ago · zacks.com

Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Beats Revenue Estimates
Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

12 days ago · prnewswire.com

Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting

15 days ago · prnewswire.com

Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries

19 days ago · prnewswire.com

Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries
Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026

26 days ago · prnewswire.com

Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer

2 months ago · prnewswire.com

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer

Earnings

Latest Earnings
Nov 4, 2026
EPS
-$0.12
Beat +3.02%
REV
$44.95M
Beat +30.66%
Next Earnings
Mar 1, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
6
Consensus
Buy
Price Target
$20.00
Upside
+420.83%
Buy (5)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.